Webinar on de-escalation of breast cancer treatments organised by EORTC and BIG
15 Oct 2020
The month of October is international breast cancer awareness month. In this context, yesterday Wednesday 14 October, the European Organisation for Research and Treatment of Cancer (EORTC) and the Breast International Group (BIG against breast cancer) organised a webinar on breast cancer addressed to the general public.
The purpose of the webinar, which counted 169 participants from different countries, was to raise awareness about breast cancer and the importance of international academic research.
The main topic of the session focussed on the growing importance of treatment de-escalation to improve breast cancer patients’ quality of life by avoiding unnecessary over-treatment. Breast cancer experts from the EORTC and BIG networks gave examples of de-escalation clinical trials and explained how they may help breast cancer patients by safely reducing treatment burden. A patient advocate from Europa Donna also gave her perspective on this topic.
If you missed the webinar, you can view the recording here.
The session included the following presentations:
- Brief introduction on global breast cancer research and de-escalation of breast cancer treatments – By Prof. Etienne Brain, EORTC Breast Cancer Group Chair & BIG Executive Board member (Brussels, Belgium)
- Brief presentation of DESCRESCENDO study and introduction of the speakers – By Prof. David Cameron, BIG Chair and EORTC Breast Cancer Group member (Edinburgh, UK)
- Tailoring radio therapy after surgery to an individual patient’s risk of recurrence (EXPERT study – BIG Radio Tuning). Tailoring radiation dose escalation after surgery: cosmetic results and patient reported outcomes informing treatment decision-making (DCIS study) – By Prof. Boon Chua, BIG Executive Board member & Study Principal Investigator of EXPERT and DCIS (Sydney, Australia)
- Using the biological characteristics of a tumour and novel diagnostic tests to help safely exclude chemotherapy (MINDACT study) – By Prof. Fatima Cardoso, EORTC Breast Cancer Group and BIG member & Study Principal Investigator of MINDACT
- Getting the patient’s perspective: Importance of giving patients the right information about de-escalation risks – By Mrs Elizabeth Bergsten Nordstrom, EUROPA DONNA Executive Board member
During the session, participants – who were a mix of breast cancer patients, advocates, family members, students, researchers and breast cancer specialists – were also invited to ask the speakers any questions they had, allowing for a true learning and sharing experience.
EORTC and BIG teams would like to thank the speakers and all participants for this interesting session!
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024